Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.76 |
| ▸ | CDK4 | P11802 | 10/20 | 0.76 |
| ▸ | PLK1 | P53350 | 4/20 | 0.76 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285606 | 0.90 | CDK2 (0.67) | CDK2CDK4PLK1CCNA2MEN1 | |
| SCHEMBL2283623 | 0.87 | CDK2 (0.77) | CDK2CDK4PLK1CCNA2MEN1 | |
| SCHEMBL4312523 | 0.86 | CDK2 (1.00) | CDK2CDK4PLK1CCNA2AURKA | |
| SCHEMBL1890923 | 0.86 | PIK3CG (0.60) | CDK2CDK4PLK1CCNA2MEN1 | |
| SCHEMBL2290008 | 0.84 | CDK2 (0.55) | CDK2CDK4PLK1CCNA2MEN1 | |
| SCHEMBL1893280 | 0.83 | CDK2 (0.57) | CDK2CDK4PLK1CCNA2MEN1 | |
| SCHEMBL2076580 | 0.83 | CDK2 (0.74) | CDK2CDK4PLK1AURKACDK7 | |
| SCHEMBL2289103 | 0.82 | CDK2 (1.00) | CDK2CDK4PLK1CCNA2AURKA | |
| SCHEMBL2283248 | 0.81 | CDK2 (0.76) | CDK2CDK4PLK1CCNA2ALDH1A1 | |
| SCHEMBL2283576 | 0.81 | CDK2 (0.59) | CDK2CDK4CCNA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288307-A1 | Anti-viral compounds | CYCLACEL LIMITED (GB) | 2005-12-29 | — | — | US | claimed |
| US-20030149057-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2003-08-07 | — | — | US | claimed |
| CN-1420884-A | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative diseases | CYCLACEL LTD (GB) | 2003-05-28 | — | — | CN | claimed |
| US-6531479-B2 | Anticancer agents, skin disorders | CYCLACEL LIMITED (GB) | 2003-03-11 | — | — | US | claimed |
| EP-1274705-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2003-01-15 | — | — | EP | claimed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | claimed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | claimed |
| CN-100355751-C | 2-substd. 4-heteroaryl-pyrimidines and their use in treatment of proliferative disorders | CYCLACEL LTD (GB) | 2007-12-19 | — | — | CN | disclosed |
| US-20050288307-A1 | Anti-viral compounds | CYCLACEL LIMITED (GB) | 2005-12-29 | — | — | US | disclosed |
| US-6699854-B2 | 2-SUBSTITUTED 4-HETEROARYL- PYRIMIDINES, INHIBITORS OF CYCLIN-DEPENDENT KINASES (CDKS) | CYCLACEL LIMITED (GB) | 2004-03-02 | — | — | US | disclosed |
| US-20030149057-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| CN-1420884-A | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative diseases | CYCLACEL LTD (GB) | 2003-05-28 | — | — | CN | disclosed |
| US-6531479-B2 | Anticancer agents, skin disorders | CYCLACEL LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1274705-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2003-01-15 | — | — | EP | disclosed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | disclosed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019404-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | CDK2 2/4885CDK4 3/4885PLK1 53/4885 |
| US-20030149057-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | CDK2 2/4885CDK4 3/4885PLK1 53/4885 |
| US-20050288307-A1 | Anti-viral compounds | MAVS, HAVCR2, EIF2AK2 | CDK2 205/4885CDK4 477/4885PLK1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.